As stated previously, all clinical studies were done prior to the discovery that TEM8/ANTXR1 is the receptor for SVV-001 on tumor and stromal cells and a potentially valuable biomarker for patients who would most benefit from therapy with SVV-001. The gene discussed is ANTXR1; the disease is neoplasm.